{
  "content": ". An analysis from the AFFIRM (Atrial Fibrillation Follow-Up Investigation of Rhythm Management) study noted excess noncardiovascular deaths with amiodarone (16).",
  "source": "https://www.jacc.org/doi/10.1016/j.jacc.2014.07.967",
  "chunk_id": "2095729b-9caf-43dc-be8d-481315b4f743",
  "similarity_score": 0.3040156960487366,
  "query": "atrial fibrillation mortality outcomes cardiovascular events stroke prevention amiodarone beta-blockers hazard ratio",
  "rank": 40,
  "title": "Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial",
  "authors": "Greg Flaker, Renato D. Lopes, Elaine Hylek, Daniel M. Wojdyla, Laine Thomas, Sana M. Al-Khatib, Renee M. Sullivan, Stefan H. Hohnloser, David Garcia, Michael Hanna, John Amerena, Veli-Pekka Harjola, Paul Dorian, Alvaro Avezum, Matyas Keltai, Lars Wallentin, Christopher B. Granger",
  "year": "2014",
  "journal": "JACC",
  "reference": "Flaker, G., Lopes, R. D., Hylek, E., Wojdyla, D. M., Thomas, L., Al-Khatib, S. M., Sullivan, R. M., Hohnloser, S. H., Garcia, D., Hanna, M., Amerena, J., Harjola, V.-P., Dorian, P., Avezum, A., Keltai, M., Wallentin, L., & Granger, C. B. (2014). Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: Insights from the ARISTOTLE trial. JACC, 64(15), 556-575.",
  "doi": "Not available",
  "chunk_index": 11,
  "total_chunks": 111,
  "retrieved_at": "2025-07-24T21:57:59.084723"
}